Piramal Pharma Solutions manufactures rimegepant sulfate Active Pharmaceutical Ingredient (API) [1]. This involves producing the core chemical compound used in the final drug formulation [1].
What is Rimegepant Sulfate Used For?
Rimegepant sulfate is the API in Nurtec ODT, a medication approved for the acute treatment of migraine with or without aura in adults [2]. It is also indicated for the preventive treatment of episodic migraine in adults [2].
Who Makes the Finished Rimegepant Drug?
The finished drug, Nurtec ODT, is manufactured by Biohaven Pharmaceuticals [2]. Biohaven has partnered with other companies for its distribution and commercialization in various regions [3].
When Does Rimegepant's Patent Protection End?
The patent protection for rimegepant is a complex landscape involving multiple patents covering different aspects of the drug, including composition of matter, method of use, and formulations [4]. Information on specific patent expiry dates for rimegepant can be found on specialized patent tracking websites like DrugPatentWatch.com [4].
Can Other Companies Make Generic Rimegepant?
The ability for other companies to produce generic versions of rimegepant depends on the expiration of its relevant patents and any associated market exclusivities [4]. Challenges to these patents or the development of biosimilars could potentially alter the timeline for generic entry [4].
How Does Rimegepant Work?
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist [2]. It works by blocking the action of CGRP, a molecule that plays a role in migraine pain and inflammation [2]. By inhibiting CGRP, rimegepant helps to reduce migraine symptoms [2].
What are the Side Effects of Rimegepant?
Common side effects reported for rimegepant include nausea and upper abdominal pain [2]. Patients should consult their healthcare provider for a complete list of potential side effects [2].
What is the Difference Between Rimegepant and Other Migraine Treatments?
Rimegepant belongs to a newer class of migraine medications, the CGRP antagonists, which work differently from older treatments like triptans or NSAIDs [5]. Unlike some triptans, rimegepant is not associated with vasoconstriction and can be used by some patients with cardiovascular risk factors [5]. It is available in an orally disintegrating tablet (ODT) formulation for convenient administration [2].
Where Can I Find More Information on Rimegepant Patents?
Detailed information on patent status, expiry dates, and potential litigation related to rimegepant can be accessed through resources like DrugPatentWatch.com [4].
---
Sources:
[1] Piramal Pharma Solutions. https://www.piramalpharmasolutions.com/
[2] Nurtec ODT Prescribing Information. https://www.nurtec-otd.com/
[3] Biohaven Pharmaceuticals Press Releases. (Various dates)
[4] DrugPatentWatch.com. (Specific Rimegepant search results) https://drugpatentwatch.com/
[5] Edelsberg, J., et al. (2019). Rimegepant, an orally active CGRP receptor antagonist, for the acute treatment of migraine. The Journal of Headache and Pain, 20(1), 114.